These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36099796)

  • 21. The evolving role of immune cells in prostate cancer.
    Wang C; Zhang Y; Gao WQ
    Cancer Lett; 2022 Jan; 525():9-21. PubMed ID: 34715253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen regulation of prostate cancer: where are we now?
    Corona G; Baldi E; Maggi M
    J Endocrinol Invest; 2011 Mar; 34(3):232-43. PubMed ID: 21297383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
    Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
    Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
    Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlamydia trachomatis infection increases the expression of inflammatory tumorigenic cytokines and chemokines as well as components of the Toll-like receptor and NF-κB pathways in human prostate epithelial cells.
    Sellami H; Said-Sadier N; Znazen A; Gdoura R; Ojcius DM; Hammami A
    Mol Cell Probes; 2014 Aug; 28(4):147-54. PubMed ID: 24613856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Castration-recurrent prostate cancer is not androgen-independent.
    Mohler JL
    Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.
    Chi JT; Lin PH; Tolstikov V; Oyekunle T; Chen EY; Bussberg V; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
    Cancer Med; 2020 Jun; 9(11):3691-3702. PubMed ID: 32232974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery.
    Tian JY; Chi CL; Bian G; Guo FJ; Wang XQ; Yu B
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):195-203. PubMed ID: 32991779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial plasticity in prostate cancer: principles and clinical perspectives.
    Das R; Gregory PA; Hollier BG; Tilley WD; Selth LA
    Trends Mol Med; 2014 Nov; 20(11):643-51. PubMed ID: 25262538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and potential targets for drug design in the androgen receptor pathway for prostate cancer.
    Guddati AK
    Expert Opin Drug Discov; 2018 Jun; 13(6):489-496. PubMed ID: 29621897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.